Loading
Before any cancer drug is made up for you, the prescription is written from an agreed treatment plan and then checked by a specially trained pharmacist or pharmacy technician: that it is the right treatment for your cancer, that the dose is worked out correctly from your height, weight and kidney function, and that your blood results are good enough for treatment that day.
The US standard is the ASCO-ONS Antineoplastic Therapy Administration Safety Standards (2024), which replaced the 2016 ASCO/ONS standards; the UK standard for the pharmacy step is BOPA's Standards for the Pharmacy Verification of Prescriptions for Cancer Medicines, version 5.0 (June 2025). Neither grades its standards: ASCO-ONS combined a systematic review (2015 to 2023) with panel opinion and public comment.
Both require prescribing from approved, standard regimens on electronic or preprinted order sets, by authorised prescribers. ASCO-ONS bans verbal orders except to hold or stop treatment, requires a supporting reference or a second practitioner for orders that depart from the standard regimen, and asks that height and weight be measured in metric units and verified by two people before a new plan. Its order must state the calculation method and variables, and how often they are rechecked.
The two differ on who verifies. BOPA says no anticancer treatment may be given or taken until a trained registered pharmacy professional has verified the prescription, and sets out checks for cycle 1 (consent, the regimen against the treatment plan, eligibility, allergies, interactions, critical tests such as cardiac function or genomic results) and for every cycle (dose calculation and units, blood results, renal and hepatic function, cumulative doses, supportive medicines, then a signature). ASCO-ONS requires a licensed pharmacist to verify all parenteral orders only where children under 18 are treated; for adults its first verification, before preparation, may be done by any personnel the organisation approves to prepare or give the treatment. BOPA asks for adult doses to be banded where national bands exist.
Why: Building each prescription from an agreed, referenced plan removes most of the room for a wrong drug, dose or schedule.
“The health care organization defines standard antineoplastic therapy regimens by diagnosis with references”
ASCO and the Oncology Nursing Society (JCO Oncology Practice; Oncology Nursing Forum) 2024
Why: Electronic order sets calculate doses and carry the protocol's supportive medicines, so less is written by hand.
“All SACT must be prescribed in the context of an approved protocol and prescribed via an electronic prescribing system.”
Why: A spoken dose or drug name is easily misheard and leaves no record to check.
“Verbal orders are not allowed except to hold or stop antineoplastic therapy administration”
ASCO and the Oncology Nursing Society (JCO Oncology Practice; Oncology Nursing Forum) 2024
Why: Changes from the usual plan are where unusual doses and wrong combinations slip through.
“The policy requires a supporting reference and/or authorization by a second licensed practitioner prior to ordering, signing, or administration of an exception order”
ASCO and the Oncology Nursing Society (JCO Oncology Practice; Oncology Nursing Forum) 2024
Why: Most doses are calculated from height and weight, so a mistake in either is carried into every drug.
“Weight and height are measured and documented in the medical record in metric units (eg, kg and cm). Both the measurement and documentation are verified by two individuals, one of whom is a licensed clinician, prior to preparation and administration of a newly prescribed antineoplastic treatment plan.”
ASCO and the Oncology Nursing Society (JCO Oncology Practice; Oncology Nursing Forum) 2024
Why: "1.0 mg" can be read as 10 mg and ".5 mg" as 5 mg; these are known causes of tenfold errors.
“Doses are written following health care organization policy for preventing the use of unapproved abbreviations, omitting trailing zeros, and including leading zeros”
ASCO and the Oncology Nursing Society (JCO Oncology Practice; Oncology Nursing Forum) 2024
Why: A separate trained check before preparation catches errors the prescriber did not see.
“SACT must not be administered by a HCP, or taken by a patient until an appropriately trained RPP has verified the prescription.”
Why: The first cycle is where a wrong regimen or a regimen for a different stage of disease is most likely to be caught.
“Check that the regimen prescribed matches the intended documented treatment plan and/or clinic letter.”
Why: Some cancer drugs interact dangerously with common medicines, herbal products or other cancer drugs.
“Check for potential interactions, contra-indications and duplication between all planned SACT & supportive medication and patient’s concurrent medication.”
Why: Some results decide whether a drug can be given at all or at what dose, such as a heart scan before an anthracycline or a DPD test before fluorouracil.
“Ensure that relevant pre-treatment critical tests have been completed and reported prior to treatment (e.g. Cardiac function, cumulative dosing, genomic testing) as these may impact eligibility for, or dosing of SACT.”
Why: Doses change as weight and kidney function change, and a unit error can mean a dose a thousand times too large.
“Check drug dose calculations (Flat, BSA, weight, AUC) and units are appropriate.”
Why: Low blood counts or poor kidney or liver function can make a normal dose dangerous.
“Check laboratory values (e.g.: FBC, U&Es LFTs) as defined within SACT protocol”
Why: Some drugs damage the heart or lungs once a total amount has been given over all cycles.
“Ensure maximum lifetime cumulative doses for e.g. anthracyclines will not be exceeded.”
Why: Anti-sickness medicines, steroids and fluids are part of giving the treatment safely, and may need changing after a reaction.
“Check pre-medications has been prescribed if appropriate, and adjusted if necessary in response to recorded toxicities”
Why: The signature shows the check was done, by whom and when.
“When satisfied that the prescription is correct sign and date prescription as a record of verification.”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Prescribe from standard, referenced regimens on electronic order sets; no verbal orders except to hold or stop; a reference or second prescriber for exception orders; height and weight in metric units verified by two people; and a trained pharmacy professional's verification of every prescription before anything is prepared or given, with a fuller check at cycle 1 (BOPA 2025; ASCO-ONS 2024). On who verifies, the two standards differ: BOPA requires a trained registered pharmacy professional for every prescription, adult or child, while ASCO-ONS requires a licensed pharmacist only where children are treated and otherwise allows the first verification by any staff the organisation approves to prepare or give the treatment. Neither standard is graded.
ASCO and the Oncology Nursing Society (JCO Oncology Practice; Oncology Nursing Forum) 2024 · British Oncology Pharmacy Association 2025
Where it differs: Rounds a calculated dose to the nearest standard band of pre-made doses, rather than making each dose to the milligram.
Evidence: BOPA asks for adult doses to be banded where bands are available, by the national dose banding tables in England, Wales and Northern Ireland or the SOPPG tables in Scotland, and says banding is not usually used in children. No outcome data were read.
Where it differs: Some clinicians cap the body surface area used to calculate doses, usually in people with obesity.
Evidence: BOPA describes capping as individual or local practice and asks only that the decision be documented in the treatment plan. ASCO's guideline on dosing in obesity, not read here, is linked from the technology record on chemotherapy dosing in obesity.
Where it differs: A trained pharmacy technician verifies simple prescriptions for later cycles, such as flat-dosed or well-tolerated drugs, instead of a pharmacist.
Evidence: BOPA version 5.0 sets the training and experience required and places technician verification within its level 2a; it is a governance standard, not a trial.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Standard regimens defined by diagnosis, with references | Standard (not graded) | ASCO and the Oncology Nursing Society (JCO Oncology Practice; Oncology Nursing Forum) 2024 |
| A licensed pharmacist verifies all parenteral orders where children under 18 are treated “A licensed pharmacist verifies all orders before dispensing parenteral antineoplastics in the health care organization that treats pediatric patients under age 18 years” | Standard (not graded) | ASCO and the Oncology Nursing Society (JCO Oncology Practice; Oncology Nursing Forum) 2024 |
| Cumulative doses tracked for drugs with cumulative toxicity “Cumulative doses of antineoplastic therapy are tracked for agents associated with cumulative toxicity” | Standard (not graded) | ASCO and the Oncology Nursing Society (JCO Oncology Practice; Oncology Nursing Forum) 2024 |
| No anticancer treatment given or taken before verification by a trained pharmacy professional | Standard (not graded) | British Oncology Pharmacy Association 2025 |
| Adult doses banded where bands exist “Note: SACT for adult patients should be dose banded where bands are available.” | Standard (not graded) | British Oncology Pharmacy Association 2025 |
Shares DPD deficiency testing before fluorouracil, capecitabine or tegafur, and dosing by the result.
Shares Carboplatin dosing by kidney function: the Calvert formula and how kidney function is measured, Dose reduction, interruption and discontinuation.
Shares Oncology pharmacy automation and compounding robots, Cytotoxic chemotherapy.
Shares Body-surface-area dosing, DPD deficiency testing before fluorouracil, capecitabine or tegafur, and dosing by the result, Dose reduction, interruption and discontinuation.
Shares Body-surface-area dosing, Full weight-based chemotherapy dosing for people with obesity, Carboplatin dosing by kidney function: the Calvert formula and how kidney function is measured, Dose reduction, interruption and discontinuation.
Shares Carboplatin dosing by kidney function: the Calvert formula and how kidney function is measured.
Shares Carboplatin dosing by kidney function: the Calvert formula and how kidney function is measured.
Shares Oncology pharmacy automation and compounding robots, Cytotoxic chemotherapy.